Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective routine care study assessing the risk of immunogenicity of patients treated with Rituximab biosimilar (GP2013) for their chronic inflammatory Rheumatic disorder

Next Previous
Trial Profile

A Prospective routine care study assessing the risk of immunogenicity of patients treated with Rituximab biosimilar (GP2013) for their chronic inflammatory Rheumatic disorder

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Methotrexate
  • Indications Connective tissue disorders; Juvenile rheumatoid arthritis; Muscular disorders; Polyarthritis; Rheumatic disorders; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
  • Focus Pharmacodynamics

Most Recent Events

  • 09 Nov 2021 Results (n=170) presented at the ACR Convergence 2021
  • 24 Jun 2021 New trial record
  • 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top